{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-013402","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.644587+00:00","generated_at":"2026-06-17T17:50:49.514357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"ADMA Q4 revenue $50M (+90% YoY); FY 2023 guidance >$210M, first-time EBITDA in H2 2023","bullets":["Q4 2022 total revenues $50.0M (+90% YoY); gross profit $14.2M (vs $3.5M); net loss $12.2M ($0.06 loss per share).","Full year 2022 revenues $154.1M (+90% YoY); net loss $65.9M (improved from $71.6M).","FY 2023 total revenue expected to exceed $210M; first-time positive EBITDA no later than second half 2023.","2024-2025 revenue targets: $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.","ASCENIV production to expand to 4,400L scale; BioCenters on track for 10 FDA-licensed sites by year-end 2023; strategic review continues with Morgan Stanley."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-013402","json":"https://secwatch.observer/filing/0001140361-23-013402.json","markdown":"https://secwatch.observer/filing/0001140361-23-013402.md","text":"https://secwatch.observer/filing/0001140361-23-013402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/0001140361-23-013402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/brhc10050204_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:50:49.514357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80d2e01ecd25cf3ebc8223dd029ab552dd78ccdf","claim":"ADMA BIOLOGICS, INC. reported the three months ended December 31, 2022 results: revenue $50.0 million.","evidence_excerpt":"Total revenues for the quarter ended December 31, 2022 were $50.0 million, as compared to $26.4 million during the fourth quarter of 2021, an increase of $23.6 million, or approximately 90%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/0001140361-23-013402-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$50.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}